Paris-based company developing an innovative treatment for patients living with chronic mucosal inflammatory diseases, Thabor Therapeutics has secured €2 million in funding from the French public investment bank Bpifrance, as part of the Deeptech Plan.
The deep tech financing will fund the research and development phases of innovative, breakthrough projects of the company prior to their industrial and commercial launch. The funding from Bpifrance is also another step towards the series A round planned for Q4 in 2022.
Inflammatory bowel diseases such as Crohn's disease and ulcerative colitis affect more than seven million people globally, with most of the cases reported in Europe and in the U.S. Founded in 2021, the biotech company specialises in the development of an innovative approach to treat patients living with chronic mucosal inflammatory diseases, in particular Inflammatory Bowel Disease (IBD). The company aims to develop drugs that specifically target newly identified gut-secreted proteins which disrupt epithelial homeostasis.
Jérémie Mariau, CEO of Thabor Therapeutics said: “Our research aims to improve patients’ long-term remission while reducing the risk of adverse side effects. It represents a major innovation in the treatment of disabling chronic inflammatory diseases, which could provide patients with a long-term solution where current treatments, notably immunosuppressive biotherapies, are failing.”